Research output: Contribution to journalReview articlepeer-review

103 Scopus citations


Zonisamide (ZNS) is a broad-spectrum antiepileptic drug in both animal models of epilepsy and patients with epilepsy. It is effective for both localization-related and generalized epilepsies and appears to be particularly potent in progressive myoclonic epilepsy syndromes. Its pharmokinetic profile is favorable, with a long half-life and low protein binding. However, its insolubility may make the development of a parenteral formulation difficult. Its safety profile is good, although teratogenicity in animal models is of concern. Adult doses of 400-600 mg per day in two doses, with blood levels from 20 to 30 mg/ml, appear to be effective.

Original languageEnglish (US)
Pages (from-to)s23-s29
Issue numberSUPPL. 5
StatePublished - 1999


  • Efficacy
  • Epilepsy
  • New antiepileptic drug
  • Side effects
  • Zonisamide


Dive into the research topics of 'Zonisamide'. Together they form a unique fingerprint.

Cite this